Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 11.4% – Time to Sell?

Ernexa Therapeutics Inc. (NASDAQ:ERNA) shares were down 11.4% during trading on Monday . The company traded as low as $0.2703 and last traded at $0.2703. Approximately 1,070,042 shares were traded during trading, a decline of 65% from the average daily volume of 3,040,254 shares. The stock had previously closed at $0.3051.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Ernexa Therapeutics has an average rating of “Sell”.

Ernexa Therapeutics Stock Performance

The stock has a 50 day moving average of $0.99 and a 200 day moving average of $1.24. The stock has a market capitalization of $2.12 million, a P/E ratio of -0.09 and a beta of 6.41.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.